Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.
2.

Improved glycaemic control--an unintended benefit of a nurse-led cardiovascular risk reduction clinic.

Woodward A, Wallymahmed M, Wilding J, Gill G.

Diabet Med. 2005 Sep;22(9):1272-4.

PMID:
16108861
3.

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group.

Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x.

PMID:
19515182
5.
6.

Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm.

Woodward A, Wallymahmed M, Wilding J, Gill G.

Diabet Med. 2006 Jul;23(7):780-7.

PMID:
16842484
8.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
9.

Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study.

Comaschi M, Coscelli C, Cucinotta D, Malini P, Manzato E, Nicolucci A; SFIDA Study Group--Italian Association of Diabetologists (AMD).

Nutr Metab Cardiovasc Dis. 2005 Jun;15(3):204-11.

PMID:
15955469
10.

Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes.

Shand B, Scott R, Connolly S, Clarke R, Baker J, Elder P, Frampton C, Yeo J.

Diabetes Obes Metab. 2007 Jul;9(4):540-7.

PMID:
17587396
12.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
13.

Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial.

Ladhani NN, Majumdar SR, Johnson JA, Tsuyuki RT, Lewanczuk RZ, Spooner R, Simpson SH.

Diabet Med. 2012 Nov;29(11):1433-9. doi: 10.1111/j.1464-5491.2012.03673.x.

PMID:
22486226
14.

Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey.

Charpentier G, Genès N, Vaur L, Amar J, Clerson P, Cambou JP, Guéret P; ESPOIR Diabetes Study Investigators.

Diabetes Metab. 2003 Apr;29(2 Pt 1):152-8.

PMID:
12746636
15.
17.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
18.

Intensified treatment of type 2 diabetes--positive effects on blood pressure, but not glycaemic control.

Gill GV, Woodward A, Pradhan S, Wallymahmed M, Groves T, English P, Wilding JP.

QJM. 2003 Nov;96(11):833-6.

PMID:
14566038
19.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
20.

Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control.

Tan CE, Chew LS, Chio LF, Tai ES, Lim HS, Lim SC, Jayakumar L, Eng HK, Packard CJ.

Diabetes Res Clin Pract. 2001 Feb;51(2):107-14.

PMID:
11165690

Supplemental Content

Support Center